Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin versus vancomycin for hospital-acquired pneumonia
ACTRN12605000324617Phase 3Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Feb 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 3 trial of telavancin in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Clinical response at test of cure evaluation. Started Feb 2005; status: completed.
02
Drugs
telavancin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on ACTRN12605000324617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000324617.